Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-12-25
2007-12-25
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S141100, C530S387300, C530S388100, C530S388250
Reexamination Certificate
active
11066262
ABSTRACT:
Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
REFERENCES:
patent: 5693762 (1997-12-01), Queen et al.
patent: 5777085 (1998-07-01), Co et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5916805 (1999-06-01), Nagano et al.
patent: 6228360 (2001-05-01), Co et al.
patent: 6280731 (2001-08-01), Nagano et al.
patent: 6613328 (2003-09-01), Co et al.
patent: 2003/0180293 (2003-09-01), Co et al.
patent: 1174575 (1998-02-01), None
patent: 0 795 608 (1997-10-01), None
patent: WO 9316185 (1993-08-01), None
patent: WO 9617078 (1996-06-01), None
Janeway et al. Immunobiology, third edition, 1997, Garland Publishing Inc., pp. 3:7-3:9.
Rudikoff et al. “Single amino acid substitutions altering antigen binding specificity”, PNAS USA, 1982, 79:1979-1983.
Amit et al. “Three-dimensional structure of an antigen-antibody complex at 2.8 angstrom reslolution” Science, 1986, 233:747-753.
“The Statistics of Sequence Similarity Scores”, downloaded from world wide web ncbi.nlm.nih.gov/BLAST/tutorial/Altschul-1.html on Nov. 4, 2005, 13 pages.
Burton et al. “Human Antibody Effector Function” Advances in Immunology, 1992, vol. 51, pp. 1-84.
Bergamaschini et al. “The role of IgG subclasses (IgG1 and/or IgG4) in the complement-activating capacity of immune complexes” J. Immunol. 1996, 156:1256-1261.
Janeway et al., Immunobiology, third edition, 1997, pp. 3:1-3:38.
Kageyma et al., Thrombosis Research, 2001, 101:395-404.
Kageyama et al., Arterioscler Thromb Vasc Biol., 2002, 22:187-192.
The Merck Manual of Diagnosis and Therapy, 17thedition, 1999, ed. Beers and Berkow, Merck Research Laboratories, pp. 1417-1427 and 1841-1845.
Bleifeld W., Eur J Clin Pharmacol, 1990, 38 Suppl 1:s73-s76.
Baumgartner et al., Annu Rev Med, 2005 56:249-272.
Cooke, JP, Vasc Med, 1997, 2:227-230.
Siegler, RL, Pediatr Clin North Am 1995, 42:1505-1529.
Kelly, KJ, Semin Nephrol, 2006, 26:105-113.
Caprioli et al., Curr Opin Crit Care, 2005, 5:487-492.
Popma et al., Chest, 2004, 126:576s-599s.
George et al., J Clin Apheresis, 1998, 13:120-125.
Amirlak et al., Nephrology, 2006, 11:213-218.
L.K. Jolliffe, “Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering”, Intern. Rev. Immunol., vol. 10, 1993, pp. 241-250.
Yamamoto, et al., “Anti-von willebrand factor antibody AJvW-2 specifically inhibits arterial but not venous thrombosis in the hamster,” BLOOD, vol. 88, supplemental 10, part 1-2, p. 677, Abstract 172A.
Kageyama, et al., “Anti-thrombotic effects and bleeding risk of AJvW-2, a monocional antibody against human von willebrand factor,” British Journal of Pharmacology, vol. 122, pp. 165-171.
Poletti, et al., “Prevention of arterial thrombosis using a novel heparin with enhanced antiplatelet activity and reduced anticoagulant activity,” Journal of Vascular Surgery, vol. 26, No. 3, pp. 366-372.
A. Manheimer-Lory, et al., “Molecular Characteristics of Antibodies Bearing An Anti-DNA-Associated Idiotype,” J. Exp. Med., vol. 174, Dec. 1991, pp. 1639-1652.
Fig. 9-11.12 of Day Hoff et al., Atlas of Protein Sequence and Structure, 5:89-99 (1972).
Jones, P. T., et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse,” Nature vol. 321, May 29, 1986, pp. 522-525.
Balint, R. F., et al., “Antibody Engineering by Parsimonious Mutagenesis,” Gene, 137 (1993), pp. 109-118.
Co Man Sung
Vasquez Maximiliano
Ajinomoto Co. Inc.
Ewoldt G. R.
Szperka Michael
LandOfFree
Methods of treating thrombotic diseases with von Willebrand... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating thrombotic diseases with von Willebrand..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating thrombotic diseases with von Willebrand... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3857356